Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukemia

Chinese Pharmaceutical Journal

Volumn 40, Issue 13, 2005, Pages 1007-1012

  Yang, Li Hua ^a   Lu, Xin Tian ^a   Lu, Wei ^b   Wu, Ke Hua ^c   Hua, Ying ^a   Zhao, Wei Hong ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Fluorescence polarization immunoassay; Methotrexate; Population pharmacokinetics

Indexed keywords

DISEASE CONTROL; DRUG DOSAGE; DRUG THERAPY; PATIENT TREATMENT; PHARMACOKINETICS; PHYSIOLOGICAL MODELS;

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL); FLUORESCENCE POLARIZATION IMMUNOASSAYS; METHOTREXATE; POPULATION PHARMACOKINETICS;

DRUG PRODUCTS;

METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN;

EID: 24944488862     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Günter H, Rüdiger F. Sis-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia(ALL-BFM 85)[J]. Blood, 1991,78:1166.
2. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies[J]. J Clin Oncol, 1994, 12:899.
3. Sheiner LB. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data[J]. J Pharmacokinet Biopharm, 1997,5(5):445.
4. Wolfrom C, Hepp R, Hartmann R, et al. Pharmacokinetic study of methotrexate, folinic acid and their plasm metabolites in children treated with high-dose methotrexate and leuoovorin rescue[J]. Eur J Clin Pharmacol, 1990,39:377.
5. Wall AM, Gajjar A, Link A, et al. Individualyzed methotrexate dosing in children with relapsed acute lymphoblastic leukemia[J]. Leukemia, 2000,14:221.
6. Odoul F, Guellec CL, Lamagenere JP, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukemia using a pupolation pharmacokinetic approach[J]. Clin Pharmacol, 1999,13:595.
7. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity[J]. J Clin Oncol, 1994,12:1667.
8. Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 1993,11:827.
9. Pinedo HM, Chabner BA. Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity[J]. Cancer Treat Rep, 1977,61:709.
10. Wang YM, Fujimoto T. Clinical pharmacyokinetics of methotrexate in children[J]. Clin Pharmacokinet, 1984,9:335.